University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Maxwell V. Meng

Maxwell V. Meng, M.D.

Urologic cancer surgeon

Dr. Maxwell Meng is a surgeon specializing in urologic cancers and laparoscopy. His clinical interests include the diagnosis and management of genitourinary malignancy and minimally invasive treatment of benign and malignant diseases. Meng, actively involved in developing new treatment technologies, is also experienced in robotic surgery.

Meng earned a medical degree at Johns Hopkins School of Medicine and completed general surgery and urology training at UCSF, where he also completed fellowships in urologic oncology and minimally invasive surgery. He is an associate professor in the UCSF Department of Urology.

Conditions & Treatments

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Risk and Prevention Clinic
1600 Divisadero St, Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Maxwell V. Meng

Education

John Hopkins University 1995

Residencies

UCSF Urology Dept., Urology 2001

Fellowships

UCSF Urology Dept., Urology 2002

Selected Research and Publications

  1. Meng MV. Editorial comment. Urology. 2012 Jan; 79(1):31.
  2. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800.
  3. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7.
  4. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60.
  5. Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol. 2011 May; 185(5):1615-20.
  6. Song G, Joe BN, Yeh BM, Meng MV, Westphalen AC, Coakley FV. Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma. Int Braz J Urol. 2011 Jan-Feb; 37(1):35-40;discussion 40-1.
  7. Eisenberg ML, Meng MV. Intracaval germ cell tumor thrombus. Urology. 2011 Jan; 77(1):70.
  8. Georgiades CS, Rodriguez R, Littrup PJ, Frangakis CE, Leveille R, Ahrar K, Atwell TD, Cadeddu J, Trimmer C, Durack JC, Hammers HJ, Meng MV, Raman S, Solomon SB, Zagoria RJ, McLennan G, Laberge JM, Gervais DA, Kee ST. Development of a research agenda for percutaneous renal tumor ablation: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2010 Dec; 21(12):1807-16.
  9. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34.
  10. Whitson JM, Reese AC, Meng MV. Factors associated with surgery in patients with renal cell carcinoma and venous tumor thrombus. BJU Int. 2011 Mar; 107(5):729-34.
  11. Meng MV. Editorial comment. Urology. 2010 Sep; 76(3):749; discussion 749.
  12. Meng MV. Editorial comment. Urology. 2010 Aug; 76(2):368-9; discussion 369.
  13. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll PR. Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int. 2010 Oct; 106(7):1022-9.
  14. Hsieh MH, Meng MV, Walsh TJ, Matthay KK, Baskin LS. Increasing incidence of neuroblastoma and potentially higher associated mortality of children from nonmetropolitan areas: analysis of the surveillance, epidemiology, and end results database. J Pediatr Hematol Oncol. 2009 Dec; 31(12):942-6.
  15. Wang ZJ, Coakley FV, Joe BN, Qayyum A, Meng MV, Yeh BM. Multidetector row CT urography: does supine or prone positioning produce better pelvecalyceal and ureteral opacification? Clin Imaging. 2009 Sep-Oct; 33(5):369-73.
  16. Meng MV. Editorial comment. The goals of minimizing resource use and treatment burden must be weighed against the risks of tumor progression and compromised cancer-specific outcomes. Urology. 2009 Jun; 73(6):1311-2.
  17. Meng M, Whitson JM. Planned renal allograft transplantation after tumor excision: increasing the availability of living-donor kidneys. Urol Oncol. 2009 Jul-Aug; 27(4):349-51.
  18. Breyer BN, Whitson JM, Freise CE, Meng MV. Prostate cancer screening and treatment in the transplant population: current status and recommendations. J Urol. 2009 May; 181(5):2018-25; discussion 2025-6.
  19. Hsieh MH, Roth DR, Meng MV. Economic analysis of infant vs postpubertal orchiopexy to prevent testicular cancer. Urology. 2009 Apr; 73(4):776-81.
  20. Wang ZJ, Meng MV, Yeh BM, Goldstein RB. Ureteral fibroepithelial polyp. J Ultrasound Med. 2008 Nov; 27(11):1647-9.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California